 <h1>Norpace CR Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>disopyramide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about disopyramide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Norpace CR.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to disopyramide: oral capsule, oral capsule extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule; Capsule, Extended Release)</p><p>An increase in mortality has been reported in patients receiving encainide or flecainide after myocardial infarction for asymptomatic non life threatening ventricular arrhythmias. Considering the known proarrhythmic properties of disopyramide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, disopyramide (the active ingredient contained in Norpace CR) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>Check with your doctor as soon as possible if any of the following side effects occur while taking disopyramide:</p><p>
<i>More common</i>
</p><ul>
<li>Dizziness, feeling of faintness</li>
<li>fainting </li>
<li>heartbeat sensations</li>
<li> shortness of breath</li>
<li>unusual tiredness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>fast or slow heartbeat, rapid weight gain, swelling of feet or lower legs</li>
<li> lightheadedness</li>
<li>rash and/or itching</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Enlargement of breasts in men</li>
<li>fever </li>
<li>mental depression</li>
<li>nosebleeds or bleeding gums</li>
<li>sore throat and fever</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Signs and symptoms of hypoglycemia (low blood sugar)</i>
</p><ul>
<li>Anxious feeling</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>drowsiness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>hunger (excessive)</li>
<li>nausea</li>
<li>nervousness</li>
<li>shakiness</li>
<li>unsteady walk</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of disopyramide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>constipation</li>
<li>dry eyes, mouth, nose, or throat</li>
<li>problems with urination</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bloating or stomach pain</li>
<li>diarrhea</li>
<li>headache</li>
<li>impotence</li>
<li> loss of appetite</li>
<li>muscle weakness</li>
<li> nausea</li>
<li>nervousness</li>
<li>trouble in sleeping</li>
</ul><p>
<!-- end oral capsule, oral capsule extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to disopyramide: compounding powder, oral capsule, oral capsule extended release</i></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects including anticholinergic side effects have been the most common cause of gastrointestinal complaints.  Dry mouth (40%), constipation (11%) and nausea, pain/bloating/gas (3% to 9%) have been reported.  Anorexia, diarrhea, and vomiting have occurred.  Two cases of paralytic ileus have been reported.  A case of oral mucosal ulceration has been associated with the (unapproved) sublingual use of disopyramide (the active ingredient contained in Norpace CR) <sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Cardiovascular side effects have included arrhythmias, conduction disturbances, hypotension, and heart failure.  Like other class I antiarrhythmic agents, disopyramide (the active ingredient contained in Norpace CR) can be proarrhythmic and decrease cardiac contractility.  The risk of proarrhythmias may be increased in patients with left ventricular dysfunction.  Various ventricular tachyarrhythmias accompanied by disopyramide-induced QT interval prolongation, including ventricular tachycardia or fibrillation and torsades de pointes, have been associated with usual therapeutic doses.  Evidence of QRS segment or QT widening are indications to either reduce the dose or stop the drug.  Conduction disturbances, including AV block, have occurred, and are more likely in patients with preexisting conduction disorders.<sup>[Ref]</sup></p><p>Contributing factors towards the development of torsades de pointes included female gender, hypokalemia, underlying arrhythmias, mitral valve abnormalities, or congestive heart failure.</p>
<p></p>
<p>Hypotension, pulmonary edema, and frank cardiogenic shock have been associated with both the oral and intravenous administration of disopyramide.  Most affected patients had underlying congestive heart failure.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>A patient developed a severe sensory-motor polyneuropathy after receiving disopyramide (the active ingredient contained in Norpace CR) 500 mg daily for 4 years.  Symptoms did not respond to corticosteroids, but did resolve a few months after withdrawal of disopyramide.<sup>[Ref]</sup></p><p>Nervous system side effects including anticholinergic symptoms have been reported.  Other nervous system side effects have been rare, and included nervousness, insomnia, depression, and peripheral paresthesia or neuropathy.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Genitourinary side effects were related to anticholinergic properties of the drug.  Urinary hesitancy (10% to 40%) has occurred.  Urinary retention, frequency, and urgency has been reported in up to 9% of patients.  Recommended management consisted of lowering the dose, discontinuing the drug, or if necessary, using a cholinergic drug to counteract this effect.  Sexual impotence has been reported.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects including reversible, dose-independent intrahepatic cholestasis, hepatocellular damage, and nonspecific hepatic inflammatory changes have been reported in rare cases where venous congestion secondary to heart failure was reasonably excluded.  Manifestations of liver dysfunction usually appeared during the first week of treatment (malaise, dark urine) and resolved promptly upon discontinuation of the drug.  In one review, 20 cases were reported during a 14-year period.<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Endocrine side effect have included hypoglycemia due to stimulation of insulin secretion and rare cases of hypokalemia and dyslipidemia.  Hypoglycemia can occur in nondiabetic patients at therapeutic plasma disopyramide (the active ingredient contained in Norpace CR) levels.<sup>[Ref]</sup></p><p>Elevated insulin levels have been measured during disopyramide-associated hypoglycemic episodes.  Data have revealed that disopyramide blocks pancreatic ATP-sensitive potassium channels, enhancing insulin release.  Other factors such as increased peripheral utilization of glucose or decreased glycogenolysis have not been fully evaluated.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Immunologic side effects, such as the production of antinuclear antibodies and other immunologically-mediated changes associated with other class 1 antiarrhythmic agents, do not appear to occur during disopyramide (the active ingredient contained in Norpace CR) therapy.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic reactions have been reported rarely, usually presenting as a rash or pruritus.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Ocular side effects of blurred vision (3% to 9%) have been associated with the anticholinergic effects of disopyramide (the active ingredient contained in Norpace CR) <sup>[Ref]</sup></p><h3>General</h3><p>General body symptoms of fatigue, muscle weakness, malaise, and aches/pains have been reported in 3% to 9% of patients administered disopyramide (the active ingredient contained in Norpace CR)   Rarely, fever has occurred.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects including reversible psychiatric symptoms of psychosis have been reported rarely.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic adverse effects of thrombocytopenia, and reversible agranulocytosis have occurred rarely.<sup>[Ref]</sup></p><h3>Other</h3><p>Gynecomastia has been reported.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory difficulty has been reported rarely.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Witkowsky AK, Reddy R, Bardy GH "Oral mucosal ulceration from disopyramide." Ann Pharmacother 29 (1995): 1299</p><p id="ref_2">2. Fulton B, Wagstaff AJ, Sorkin EM "Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia." Drugs 2 (1995): 295-320</p><p id="ref_3">3. Ahmad S "Disopyramide-related paralytic ileus: case report." J Am Geriatr Soc 39 (1991): 317-8</p><p id="ref_4">4. "Product Information. Norpace (disopyramide)." Searle, Skokie, IL. </p><p id="ref_5">5. Ekelund LG, Nilsson E, Walldius G "Efficacy of and adverse effects of disopyramide." Eur J Clin pharmacol 29 (1986): 673-7</p><p id="ref_6">6. Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990): 1146</p><p id="ref_7">7. Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980): 665-8</p><p id="ref_8">8. Brogden RN, Todd PA "Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias." Drugs 34 (1987): 151-87</p><p id="ref_9">9. Bauman JL, Gallasategui J, Strasberg B, et al "Long-term therapy with disopyramide phosphate: side effects and effectiveness." Am Heart J 111 (1986): 654-60</p><p id="ref_10">10. Simpson RJ, Foster JR, Benge C, et al "Safety of multiple bolus loading of intravenous disopyramide." Am Heart J 106 (1983): 505-8</p><p id="ref_11">11. Timins BI, Gutman JA, Haft JI "Disopyramide-induced heart block." Chest 79 (1981): 477-9</p><p id="ref_12">12. Masuhara K, Ohno T, Hamaguchi K, Katoh K, Kashiwada K, Takahashi S, Tanaka Y, Someya K, Ogata H "Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-n-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients." Int J Clin Pharmacol Res 15 (1995): 103-13</p><p id="ref_13">13. Bauman DJ "Myocardial depression with disopyramide." Ann Intern Med 94 (1981): 411-2</p><p id="ref_14">14. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993): 2590-7</p><p id="ref_15">15. Sinatra ST, Landry AB, Galle JS, Amato J "Cariogenic shock associated with disopyramide phosphate." JAMA 243 (1980): 1132</p><p id="ref_16">16. Timins BI "Disopyramide and bundle-branch block." Ann Intern Med 96 (1982): 684</p><p id="ref_17">17. Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983): 870-1</p><p id="ref_18">18. Tonkin AM, Joel SE, Reynolds JL "Unusual hepatocellular and cardiovascular complications of disopyramide." Chest 77 (1980): 125</p><p id="ref_19">19. Desai JM, Scheinman MM, Hirschfeld D, et al "Cardiovascular collapse associated with disopyramide therapy." Chest 79 (1981): 545-51</p><p id="ref_20">20. Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982): 110-4</p><p id="ref_21">21. Porterfield JG, Antman EM, Lown B "Respiratory difficulty after use of disopyramide." N Engl J Med 303 (1980): 584</p><p id="ref_22">22. Podrid PJ, Schoeneberger A, Lown B "Congestive heart failure caused by oral disopyramide." N Engl J Med 302 (1980): 614-7</p><p id="ref_23">23. Lo KS, Gantz KB, Stetson PL, et al "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980): 413-4</p><p id="ref_24">24. Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981): 946-7</p><p id="ref_25">25. Teichman SL, Ferrick A, Kim SG, et al "Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect." J AM Coll Cardiol 10 (1987): 633-41</p><p id="ref_26">26. Teichman SL, Fisher JD, Matos JA, Kim SG "Disopyramide-pyridostigmine: report of a beneficial drug interaction." J Cardiovasc Pharmacol 7 (1985): 108-13</p><p id="ref_27">27. Briani C,  Zara G,  Negrin P "Disopyramide-induced neuropathy." Neurology 58 (2002): 663</p><p id="ref_28">28. Ahmad S "Disopyramide and impotence." South Med J 73 (1980): 958</p><p id="ref_29">29. Danziger LH, Horn JR "Disopyramide-induced urinary retention." Arch Intern Med 143 (1983): 1683-6</p><p id="ref_30">30. Bakris GL, Cross PD, Hammarsten JE "Disopyramide-associated liver dysfunction." Mayo Clin proc 58 (1983): 265-7</p><p id="ref_31">31. Antonelli D, Koltun B, Barzilay J "Acute hepatotoxic effect of disopyramide." Chest 86 (1984): 274</p><p id="ref_32">32. Craxi A, Gatto G, Maringhini A, et al "Disopyramide and cholestasis." Ann Intern Med 93 (1980): 150-1</p><p id="ref_33">33. Doody PT "Disopyramide hepatotoxicity and disseminated intravascular coagulation." South Med J 75 (1982): 496-8</p><p id="ref_34">34. Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1</p><p id="ref_35">35. Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8</p><p id="ref_36">36. Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7</p><p id="ref_37">37. Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42</p><p id="ref_38">38. Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8</p><p id="ref_39">39. Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6</p><p id="ref_40">40. Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424</p><p id="ref_41">41. Wanner WR, Irvin WS "Disopyramide and antinuclear antibodies." Am Heart J 101 (1981): 687-9</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Norpace CR (disopyramide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: group I antiarrhythmics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Norpace CR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Norpace</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Arrhythmia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to disopyramide: compounding powder, oral capsule, oral capsule extended release</i></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects including anticholinergic side effects have been the most common cause of gastrointestinal complaints.  Dry mouth (40%), constipation (11%) and nausea, pain/bloating/gas (3% to 9%) have been reported.  Anorexia, diarrhea, and vomiting have occurred.  Two cases of paralytic ileus have been reported.  A case of oral mucosal ulceration has been associated with the (unapproved) sublingual use of disopyramide (the active ingredient contained in Norpace CR) <sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Cardiovascular side effects have included arrhythmias, conduction disturbances, hypotension, and heart failure.  Like other class I antiarrhythmic agents, disopyramide (the active ingredient contained in Norpace CR) can be proarrhythmic and decrease cardiac contractility.  The risk of proarrhythmias may be increased in patients with left ventricular dysfunction.  Various ventricular tachyarrhythmias accompanied by disopyramide-induced QT interval prolongation, including ventricular tachycardia or fibrillation and torsades de pointes, have been associated with usual therapeutic doses.  Evidence of QRS segment or QT widening are indications to either reduce the dose or stop the drug.  Conduction disturbances, including AV block, have occurred, and are more likely in patients with preexisting conduction disorders.<sup>[Ref]</sup></p><p>Contributing factors towards the development of torsades de pointes included female gender, hypokalemia, underlying arrhythmias, mitral valve abnormalities, or congestive heart failure.</p><p></p><p>Hypotension, pulmonary edema, and frank cardiogenic shock have been associated with both the oral and intravenous administration of disopyramide.  Most affected patients had underlying congestive heart failure.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>A patient developed a severe sensory-motor polyneuropathy after receiving disopyramide (the active ingredient contained in Norpace CR) 500 mg daily for 4 years.  Symptoms did not respond to corticosteroids, but did resolve a few months after withdrawal of disopyramide.<sup>[Ref]</sup></p><p>Nervous system side effects including anticholinergic symptoms have been reported.  Other nervous system side effects have been rare, and included nervousness, insomnia, depression, and peripheral paresthesia or neuropathy.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Genitourinary side effects were related to anticholinergic properties of the drug.  Urinary hesitancy (10% to 40%) has occurred.  Urinary retention, frequency, and urgency has been reported in up to 9% of patients.  Recommended management consisted of lowering the dose, discontinuing the drug, or if necessary, using a cholinergic drug to counteract this effect.  Sexual impotence has been reported.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects including reversible, dose-independent intrahepatic cholestasis, hepatocellular damage, and nonspecific hepatic inflammatory changes have been reported in rare cases where venous congestion secondary to heart failure was reasonably excluded.  Manifestations of liver dysfunction usually appeared during the first week of treatment (malaise, dark urine) and resolved promptly upon discontinuation of the drug.  In one review, 20 cases were reported during a 14-year period.<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Endocrine side effect have included hypoglycemia due to stimulation of insulin secretion and rare cases of hypokalemia and dyslipidemia.  Hypoglycemia can occur in nondiabetic patients at therapeutic plasma disopyramide (the active ingredient contained in Norpace CR) levels.<sup>[Ref]</sup></p><p>Elevated insulin levels have been measured during disopyramide-associated hypoglycemic episodes.  Data have revealed that disopyramide blocks pancreatic ATP-sensitive potassium channels, enhancing insulin release.  Other factors such as increased peripheral utilization of glucose or decreased glycogenolysis have not been fully evaluated.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Immunologic side effects, such as the production of antinuclear antibodies and other immunologically-mediated changes associated with other class 1 antiarrhythmic agents, do not appear to occur during disopyramide (the active ingredient contained in Norpace CR) therapy.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic reactions have been reported rarely, usually presenting as a rash or pruritus.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Ocular side effects of blurred vision (3% to 9%) have been associated with the anticholinergic effects of disopyramide (the active ingredient contained in Norpace CR) <sup>[Ref]</sup></p><h3>General</h3><p>General body symptoms of fatigue, muscle weakness, malaise, and aches/pains have been reported in 3% to 9% of patients administered disopyramide (the active ingredient contained in Norpace CR)   Rarely, fever has occurred.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects including reversible psychiatric symptoms of psychosis have been reported rarely.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic adverse effects of thrombocytopenia, and reversible agranulocytosis have occurred rarely.<sup>[Ref]</sup></p><h3>Other</h3><p>Gynecomastia has been reported.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory difficulty has been reported rarely.<sup>[Ref]</sup></p><p id="ref_1">1. Witkowsky AK, Reddy R, Bardy GH "Oral mucosal ulceration from disopyramide." Ann Pharmacother 29 (1995): 1299</p><p id="ref_2">2. Fulton B, Wagstaff AJ, Sorkin EM "Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia." Drugs 2 (1995): 295-320</p><p id="ref_3">3. Ahmad S "Disopyramide-related paralytic ileus: case report." J Am Geriatr Soc 39 (1991): 317-8</p><p id="ref_4">4. "Product Information. Norpace (disopyramide)." Searle, Skokie, IL. </p><p id="ref_5">5. Ekelund LG, Nilsson E, Walldius G "Efficacy of and adverse effects of disopyramide." Eur J Clin pharmacol 29 (1986): 673-7</p><p id="ref_6">6. Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990): 1146</p><p id="ref_7">7. Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980): 665-8</p><p id="ref_8">8. Brogden RN, Todd PA "Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias." Drugs 34 (1987): 151-87</p><p id="ref_9">9. Bauman JL, Gallasategui J, Strasberg B, et al "Long-term therapy with disopyramide phosphate: side effects and effectiveness." Am Heart J 111 (1986): 654-60</p><p id="ref_10">10. Simpson RJ, Foster JR, Benge C, et al "Safety of multiple bolus loading of intravenous disopyramide." Am Heart J 106 (1983): 505-8</p><p id="ref_11">11. Timins BI, Gutman JA, Haft JI "Disopyramide-induced heart block." Chest 79 (1981): 477-9</p><p id="ref_12">12. Masuhara K, Ohno T, Hamaguchi K, Katoh K, Kashiwada K, Takahashi S, Tanaka Y, Someya K, Ogata H "Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-n-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients." Int J Clin Pharmacol Res 15 (1995): 103-13</p><p id="ref_13">13. Bauman DJ "Myocardial depression with disopyramide." Ann Intern Med 94 (1981): 411-2</p><p id="ref_14">14. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993): 2590-7</p><p id="ref_15">15. Sinatra ST, Landry AB, Galle JS, Amato J "Cariogenic shock associated with disopyramide phosphate." JAMA 243 (1980): 1132</p><p id="ref_16">16. Timins BI "Disopyramide and bundle-branch block." Ann Intern Med 96 (1982): 684</p><p id="ref_17">17. Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983): 870-1</p><p id="ref_18">18. Tonkin AM, Joel SE, Reynolds JL "Unusual hepatocellular and cardiovascular complications of disopyramide." Chest 77 (1980): 125</p><p id="ref_19">19. Desai JM, Scheinman MM, Hirschfeld D, et al "Cardiovascular collapse associated with disopyramide therapy." Chest 79 (1981): 545-51</p><p id="ref_20">20. Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982): 110-4</p><p id="ref_21">21. Porterfield JG, Antman EM, Lown B "Respiratory difficulty after use of disopyramide." N Engl J Med 303 (1980): 584</p><p id="ref_22">22. Podrid PJ, Schoeneberger A, Lown B "Congestive heart failure caused by oral disopyramide." N Engl J Med 302 (1980): 614-7</p><p id="ref_23">23. Lo KS, Gantz KB, Stetson PL, et al "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980): 413-4</p><p id="ref_24">24. Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981): 946-7</p><p id="ref_25">25. Teichman SL, Ferrick A, Kim SG, et al "Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect." J AM Coll Cardiol 10 (1987): 633-41</p><p id="ref_26">26. Teichman SL, Fisher JD, Matos JA, Kim SG "Disopyramide-pyridostigmine: report of a beneficial drug interaction." J Cardiovasc Pharmacol 7 (1985): 108-13</p><p id="ref_27">27. Briani C,  Zara G,  Negrin P "Disopyramide-induced neuropathy." Neurology 58 (2002): 663</p><p id="ref_28">28. Ahmad S "Disopyramide and impotence." South Med J 73 (1980): 958</p><p id="ref_29">29. Danziger LH, Horn JR "Disopyramide-induced urinary retention." Arch Intern Med 143 (1983): 1683-6</p><p id="ref_30">30. Bakris GL, Cross PD, Hammarsten JE "Disopyramide-associated liver dysfunction." Mayo Clin proc 58 (1983): 265-7</p><p id="ref_31">31. Antonelli D, Koltun B, Barzilay J "Acute hepatotoxic effect of disopyramide." Chest 86 (1984): 274</p><p id="ref_32">32. Craxi A, Gatto G, Maringhini A, et al "Disopyramide and cholestasis." Ann Intern Med 93 (1980): 150-1</p><p id="ref_33">33. Doody PT "Disopyramide hepatotoxicity and disseminated intravascular coagulation." South Med J 75 (1982): 496-8</p><p id="ref_34">34. Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1</p><p id="ref_35">35. Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8</p><p id="ref_36">36. Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7</p><p id="ref_37">37. Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42</p><p id="ref_38">38. Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8</p><p id="ref_39">39. Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6</p><p id="ref_40">40. Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424</p><p id="ref_41">41. Wanner WR, Irvin WS "Disopyramide and antinuclear antibodies." Am Heart J 101 (1981): 687-9</p><h2>More about Norpace CR (disopyramide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: group I antiarrhythmics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Norpace CR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Norpace</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Arrhythmia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>